Aclaris Eyes Breakout on Upcoming Clinical Results
AI Prediction of Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, shows potential for significant stock price movement due to its focused development on novel drug candidates for immuno-inflammatory diseases. The recent inclusion in the Russell 2000 and 3000 indexes, alongside promising clinical trial advancements for its key drug candidates, positions ACRS as a potentially attractive investment opportunity.
ACRS Report Information
Prediction Date2025-07-03 06:00:43
Close @ Prediction$1.44
Mkt Cap169m
IPO Date2015-10-07
AI-derived Information
Recent News for ACRS
- Aug 17 — Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138 (Insider Monkey)
- Aug 7 — Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
- Aug 7 — Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
- Aug 7 — Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
- Aug 4 — Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
- Jul 30 — Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
- Jul 29 — Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints (GlobeNewswire)
- Jul 28 — Aclaris Therapeutics Announces Leadership Transition (GlobeNewswire)
- Jul 15 — Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases (Insider Monkey)
- Jun 30 — Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.